USPTO 2015–2025 USPTO PatentsView US Corporation

Locl Pharma, Inc.

USPTO PatentsView assignee record - 14 granted patents across 2 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Locl ranks #20,022 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 2 technology areas.

#20,022
of 49,997 US assignees by volume
30th percentile
by Innovation Score (29.4/100)
34.6
avg claims per patent
-92%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R20022 · US Corporation #20,022 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 14 grants
  • MID-PACK #20,022/49,997
  • PHOTO-FINISH LIA Diagnostics
  • CPC-NARROW A61P · 2 areas
  • INNOV-THIN 29.4/100
  • CLAIMS-DENSE 34.6 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -92% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: LIA Diagnostics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Locl’s 29.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Locl

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Locl's Innovation Score is 29.4/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Locl?

Each dot is one of Locl’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Locl’s own 34.6 claims/patent is ABOVE the 10.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Locl vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 13.913.91414.1 010203040 Granted patents (volume) Avg claims / patent LIA Diagnostics, Inc. - 14, 7.79LIA DiagnosticsLiebherr-elektronik GMBH - 14, 13.14Liebherr-elektron…Lindsey Manufacturing Co. - 14, 21.21Lindsey Manufactu…Livingstyle Enterprises Limited - 14, 10.93Livingstyle Enter…Locus OIL IP Company, LLC - 14, 9.64Locus OIL IPLogan Clutch Corporation - 14, 23.57Logan ClutchLogue AND Co. PTY Ltd., AS Trustee FOR A.T. & L.M. Logue Family Trust - 14, 1Logue AND PTY AS…Lontra Limited - 14, 18.57LontraLocl Pharma, Inc. - 14, 34.57Locl Pharma
Locl vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Locl's grants concentrate

Locl Pharma, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (9 grants) versus a trough of 1 in 2020. By volume, Locl sits between LIA Diagnostics, Inc. and Lontra Limited.

Who files at Locl's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Locl holds 14 patents at rank #20,005, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Locl

By rank, the assignees closest to #20,005 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Locl's primary technology class.

Locl's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 30th percentile higher than 30% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0246810 2016201720182020 1
USPTO utility patent grants by year · 2016–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Locl Pharma, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 9 64.3%
2017 2 14.3%
2018 2 14.3%
2020 1 7.1%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Locl Pharma, Inc.'s patent record in context - here's where to go next.

  • Locl Pharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #20,022 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Locl Pharma, Inc. against LIA Diagnostics, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 29.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.